Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.

IF 1.4 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Journal of International Medical Research Pub Date : 2025-02-01 DOI:10.1177/03000605241311437

Malik Waleed Zeb Khan, Aizaz Ali, Amna Hussain, Safeena Khan, Ammara Tahir, Muhammad Haris Khan, Touba Azeem, Abdul Moeez, Arysha Monis, Aban Masaud Mian, Fazia Khattak, Moosa Ali, Jibran Ikram

{"title":"Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.","authors":"Malik Waleed Zeb Khan, Aizaz Ali, Amna Hussain, Safeena Khan, Ammara Tahir, Muhammad Haris Khan, Touba Azeem, Abdul Moeez, Arysha Monis, Aban Masaud Mian, Fazia Khattak, Moosa Ali, Jibran Ikram","doi":"10.1177/03000605241311437","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the safety and efficacy of laquinimod in treating relapsing-remitting multiple sclerosis (RRMS).Methods: An extensive electronic search was conducted across PubMed, Embase, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov to identify suitable studies. Risk of bias was assessed using Cochrane's Risk of Bias tool. Statistical analysis was performed using RevMan 5.4.1.Results: The meta-analysis of four randomized controlled trials including 3665 patients found that laquinimod significantly reduced the annualized relapse rate compared with placebo (mean difference = -0.08, 95% confidence interval [CI] = -0.12, -0.04, I2 = 0%). For disability progression confirmed at 3 months, laquinimod provided a significant advantage over placebo (hazard ratio [HR] = 0.75, 95% CI = 0.59, 0.96, I2 = 25%), whereas no benefit was achieved at 6 months (HR = 0.69, 95% CI = 0.45, 1.06, I2 = 66%). Laquinimod was also significantly better than placebo in maintaining a relapse-free status (risk ratio [RR] = 1.14 95% CI = 1.06, 1.22, I2 = 10%). Laquinimod had a comparable safety profile as placebo (RR = 1.06, 95% CI = 0.81, 1.39, I2 = 33%).Conclusions: These findings support the efficacy of laquinimod in managing RRMS but necessitate careful monitoring during treatment.","PeriodicalId":16129,"journal":{"name":"Journal of International Medical Research","volume":"53 2","pages":"3000605241311437"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11806468/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03000605241311437","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the safety and efficacy of laquinimod in treating relapsing-remitting multiple sclerosis (RRMS).

Methods: An extensive electronic search was conducted across PubMed, Embase, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov to identify suitable studies. Risk of bias was assessed using Cochrane's Risk of Bias tool. Statistical analysis was performed using RevMan 5.4.1.

Results: The meta-analysis of four randomized controlled trials including 3665 patients found that laquinimod significantly reduced the annualized relapse rate compared with placebo (mean difference = -0.08, 95% confidence interval [CI] = -0.12, -0.04, I² = 0%). For disability progression confirmed at 3 months, laquinimod provided a significant advantage over placebo (hazard ratio [HR] = 0.75, 95% CI = 0.59, 0.96, I² = 25%), whereas no benefit was achieved at 6 months (HR = 0.69, 95% CI = 0.45, 1.06, I² = 66%). Laquinimod was also significantly better than placebo in maintaining a relapse-free status (risk ratio [RR] = 1.14 95% CI = 1.06, 1.22, I² = 10%). Laquinimod had a comparable safety profile as placebo (RR = 1.06, 95% CI = 0.81, 1.39, I² = 33%).

Conclusions: These findings support the efficacy of laquinimod in managing RRMS but necessitate careful monitoring during treatment.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of International Medical Research 医学-药学

CiteScore

3.20

自引率

0.00%

发文量

555

审稿时长

1 months

期刊介绍： _Journal of International Medical Research_ is a leading international journal for rapid publication of original medical, pre-clinical and clinical research, reviews, preliminary and pilot studies on a page charge basis. As a service to authors, every article accepted by peer review will be given a full technical edit to make papers as accessible and readable to the international medical community as rapidly as possible. Once the technical edit queries have been answered to the satisfaction of the journal, the paper will be published and made available freely to everyone under a creative commons licence. Symposium proceedings, summaries of presentations or collections of medical, pre-clinical or clinical data on a specific topic are welcome for publication as supplements. Print ISSN: 0300-0605